Clinical trials: Prostatic Hypertrophy, Benign
Prostate Cancer
Safety and Efficacy of Two-step Radical Prostatectomy
The goal of this observational study is to learn about the safety and efficacy of two-step radical prostatectomy in the treatment of low- to intermediate-risk prostate cancer patient with enlarged prostate and severe benign…
- Trial name
- NCT05722392
- Testing
- Two-step Radical Prostatectomy
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sun Yat-sen University
Prostatic Hyperplasia
Observational Study in Patients With Functional Benign Prostatic Hyperplasia Symptoms Who Switched From Phytotherapy to ALNA® (Tamsulosin)
The objective of the observational study were to investigate the switch from phytotherapy to ALNA® after at least 4 weeks of phytotherapy and still presented with a symptom sum score of ≥ 8 points (International Prostate Symptom…
- Trial name
- NCT02244320
- Testing
- Tamsulosin
- Volunteers
- 4,150 people
- Sponsor
- Boehringer Ingelheim
Benign Prostate Hyperplasia
A Trial Assessing Peri-procedure Chemoprophylaxis During Transrectal Prostate Needle Biopsy
The aim of the study is to evaluate whether changing antibiotic prophylaxis from fluoroquinolones alone to fluoroquinolones plus gentamicin 160mg single IM dose or targeted antibiotic prophylaxis according to rectal swab culture…
- Trial name
- NCT02423759
- Testing
- ciprofloxacin, ciprofloxacin and gentamycine, culture based chemoprophylaxis
- Where
- Egypt
- Volunteers
- 510 people
- Sponsor
- Mansoura University
Benign Prostatic Hyperplasia
Optilume BPH Catheter System in Benign Prostatic Hyperplasia (BPH)
A post-marketing study using Optilume Catheter System for benign prostatic hyperplasia.
- Trial name
- SUMMIT (NCT05567666)
- Testing
- Optilume Catheter System
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- Dean Elterman
Prostatic Hyperplasia
Safety Profile of Secotex ® in Patients With Benign Prostatic Hyperplasia
The Objective of this study is to conduct a Prescription Event Monitoring (PEM) involving patients treated with Secotex® (Tamsulosin) in "real life" settings.
- Trial name
- NCT02245529
- Testing
- Tamsulosin
- Volunteers
- 982 people
- Sponsor
- Boehringer Ingelheim
Lower Urinary Tract Symptoms Caused by Benign Prostatic Enlargement (LUTS BPE), Prostate Artery Embolisation (PAE)
ROPE Registry Project to Determine the Safety and Efficacy of Prostate Artery Embolisation (PAE) for Lower Urinary Tract Symptoms Secondary to Benign Prostatic Enlargement (LUTS BPE).
This is a study protocol for the UK ROPE Register for Lower Urinary Tract Symptoms (LUTS). This register enables us to collect data on the treatment of LUTS using prostate artery embolisation (PAE), and other surgical methods to…
- Conditions
- Lower Urinary Tract Symptoms Caused by Benign Prostatic Enlargement (LUTS BPE), Prostate Artery Embolisation (PAE), Transurethral Resection of the Prostate (TURP), Open Prostatectomy
- Trial name
- UKROPE (NCT02849522)
- Testing
- Prostatic Artery Embolisation, TURP, Open prostatectomy
- Volunteers
- 300 people
- Sponsor
- Cedar, United Kingdom
Bladder Cancer
Loop Resectoscope in Treating Patients With Bladder Cancer or Benign Prostatic Hyperplasia Who Are Undergoing Transurethral Resection
RATIONALE: Transurethral resection is a less invasive type of surgery for bladder cancer or benign prostatic hyperplasia. Transurethral resection using a loop resectoscope may have fewer side effects and improve recovery.
- Trial name
- NCT00303654
- Testing
- biopsy, therapeutic conventional surgery
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Roei Medical Technologies Ltd.
Prostate Cancer, Benign Prostatic Hyperplasia
Annexin A3 (ANXA3) as Protein-Based Marker for Non-Invasive Molecular Diagnostics of Prostate Carcinoma
Emerging from a differential proteomic study of sample pairs of prostate cancer and benign tissue, annexin A3 (ANXA3) was chosen as a potential novel biomarker for the early and non-invasive diagnosis of prostate cancer.
- Conditions
- Prostate Cancer, Benign Prostatic Hyperplasia, Prostatic Intraepithelial Neoplasia
- Trial name
- NCT00400894
- Volunteers
- 750 people
- Sponsor
- ProteoSys AG